LPCN – Lipocine Inc
Lipocine Inc.
LPCN
$4.66Name : Lipocine Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $24,921,400.00
EPSttm : -1.62
Lipocine Inc.
$4.66
4.02%
$0.18
Fair Value
Margin Of Safety %
Put/Call OI Ratio
Float Short %
2.67
EPS 1 Diff
EPS Year Diff
2.32
Ticker: LPCN
21 items
«
‹
of 1
›
»
Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
---|---|---|---|---|---|
2024-09-06 | LPCN | 3.5901 | N/A | N/A | 0 |
2024-09-09 | LPCN | 3.73 | N/A | N/A | 0 |
2024-09-10 | LPCN | 4.06 | N/A | N/A | 0 |
2024-09-11 | LPCN | 3.8501 | N/A | N/A | 0 |
2024-09-12 | LPCN | 4.075 | N/A | N/A | 0 |
2024-09-13 | LPCN | 4.65 | N/A | N/A | 0 |
2024-09-16 | LPCN | 4.77 | N/A | N/A | 0 |
2024-09-17 | LPCN | 4.91 | N/A | N/A | 0 |
2024-09-18 | LPCN | 4.96 | N/A | N/A | 0 |
2024-09-19 | LPCN | 4.9 | N/A | N/A | 0 |
2024-09-20 | LPCN | 4.9104 | N/A | N/A | 0 |
2024-09-23 | LPCN | 4.62 | N/A | N/A | 0 |
2024-09-24 | LPCN | 4.5 | N/A | N/A | 0 |
2024-09-25 | LPCN | 4.64 | N/A | N/A | 0 |
2024-09-26 | LPCN | 4.5 | N/A | N/A | 0 |
2024-09-27 | LPCN | 4.39 | N/A | N/A | 0 |
2024-09-30 | LPCN | 4.43 | N/A | N/A | 0 |
2024-10-01 | LPCN | 4.24 | N/A | N/A | 0 |
2024-10-02 | LPCN | 4.25 | N/A | N/A | 0 |
2024-10-03 | LPCN | 4.58 | N/A | N/A | 0 |
2024-10-04 | LPCN | 4.67 | N/A | N/A | 0 |
Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
---|---|---|---|---|---|
2024-09-06 | LPCN | 3.66 | 70.1 | - | -0.92 |
2024-09-09 | LPCN | 3.69 | 70.1 | - | -0.92 |
2024-09-10 | LPCN | 3.98 | 70.1 | - | -0.92 |
2024-09-11 | LPCN | 3.85 | 70.1 | - | -0.92 |
2024-09-12 | LPCN | 4.32 | 70.1 | - | -0.92 |
2024-09-13 | LPCN | 4.55 | 70.1 | - | -0.92 |
2024-09-16 | LPCN | 4.80 | 70.1 | - | -0.92 |
2024-09-17 | LPCN | 4.84 | 70.1 | - | -0.92 |
2024-09-18 | LPCN | 5.07 | 70.1 | - | -0.92 |
2024-09-19 | LPCN | 4.77 | 70.1 | - | -0.92 |
2024-09-20 | LPCN | 4.74 | 70.1 | - | -0.92 |
2024-09-23 | LPCN | 4.62 | 70.1 | - | -0.92 |
2024-09-24 | LPCN | 4.61 | 70.1 | - | -0.92 |
2024-09-25 | LPCN | 4.64 | 70.1 | - | -0.92 |
2024-09-26 | LPCN | 4.64 | 70.1 | - | -0.92 |
2024-09-27 | LPCN | 4.44 | 70.1 | - | -0.78 |
2024-09-30 | LPCN | 4.44 | 62.2 | - | -0.78 |
2024-10-01 | LPCN | 4.31 | 62.2 | - | -0.78 |
2024-10-02 | LPCN | 4.49 | 62.2 | - | -0.78 |
2024-10-03 | LPCN | 4.51 | 62.2 | - | -0.78 |
2024-10-04 | LPCN | 4.66 | 62.2 | - | -0.78 |
Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
---|---|---|---|---|
2024-09-06 | LPCN | 0.00 | -63.19 | 2.72 |
2024-09-09 | LPCN | 0.00 | -63.19 | 2.72 |
2024-09-10 | LPCN | 0.00 | -63.19 | 2.72 |
2024-09-11 | LPCN | 0.00 | -63.19 | 2.72 |
2024-09-12 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-13 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-16 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-17 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-18 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-19 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-20 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-23 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-24 | LPCN | 0.00 | -63.19 | 2.59 |
2024-09-25 | LPCN | 0.00 | -63.19 | 2.67 |
2024-09-26 | LPCN | 0.00 | -63.19 | 2.67 |
2024-09-27 | LPCN | 0.00 | -63.19 | 2.67 |
2024-09-30 | LPCN | 0.00 | -63.19 | 2.67 |
2024-10-01 | LPCN | 0.00 | -63.19 | 2.67 |
2024-10-02 | LPCN | 0.00 | -63.19 | 2.67 |
2024-10-03 | LPCN | 0.00 | -63.19 | 2.67 |
2024-10-04 | LPCN | 0.00 | -63.19 | 2.67 |
Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.26
Insider Transactions
Institutional Transactions
-63.19
Beta
1.22
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value (Academic)
Quality Score
23
Growth Score
29
Sentiment Score
17
Actual DrawDown %
91.6
Max Drawdown 5-Year %
-95.6
Target Price
21.5
P/E
Forward P/E
PEG
P/S
3.21
P/B
1.18
P/Free Cash Flow
EPS
-1.62
Average EPS Est. Cur. Y
-0.78
EPS Next Y. (Est.)
-1.24
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-109.36
Relative Volume
0.92
Return on Equity vs Sector %
-61.6
Return on Equity vs Industry %
-82.8
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.14
EBIT Estimation
Lipocine Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 17
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
stock quote shares LPCN – Lipocine Inc Stock Price stock today
news today LPCN – Lipocine Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPCN – Lipocine Inc yahoo finance google finance
stock history LPCN – Lipocine Inc invest stock market
stock prices LPCN premarket after hours
ticker LPCN fair value insiders trading